Estancia La Jolla Hotel & Spa Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2016



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

New Therapeutics for Diabetes and Obesity (G1)


Organizer(s) Richard D. DiMarchi, Matthias H. Tschöp and Nancy A. Thornberry
April 17—20, 2016
Estancia La Jolla Hotel & Spa • La Jolla, California USA
Discounted Abstract Deadline: Dec 16, 2015
Abstract Deadline: Jan 19, 2016
Scholarship Deadline: Dec 16, 2015
Discounted Registration Deadline: Feb 16, 2016

Sponsored by Arena Pharmaceuticals, Inc., Janssen R&D: Pharmaceutical Companies of Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S and Regeneron Pharmaceuticals, Inc.

Summary of Meeting:
Type 2 diabetes (T2DM) is a global pandemic with approximately 350 million patients worldwide, driven largely by increasing prevalence of obesity. Multiple options exist for treatment of the primary disease and the array of associated cardiovascular disorders. Nonetheless, the majority of patients do not reach recommended glycemic goals, and there is an urgent need for more efficacious, cost-effective and safe therapies. The regulatory hurdle for new drugs is sizable and challenged by the specific requirement for cardiovascular mortality study. Given the magnitude of the challenges, highly collaborative efforts involving academia, biotech, pharma, regulatory agencies, patient advocacy groups and other key stakeholders are required to identify and advance new therapies that are substantially differentiated from current disease management. The major goals of this meeting are to: 1) Define the distance between current therapy relative to what is most needed to address successfully the near-term challenges of the disease and the wave of later-stage disease-specific complications; 2) Communicate the most important scientific advances in metabolic diseases with the intimate details that often escape peer-review publication and are seminal to drug R&D; and 3) Create opportunities for candid discussion among key stakeholders (academia, biotech, industry, regulatory, venture community, etc.) to identify new business processes, along with new science to streamline the successful conversion of ideas to medicines. Is it anticipated that the perspectives and science presented at this meeting, together with multiple platforms for discussion and interaction, will facilitate the identification of collaborations and opportunities for the discovery of transformative treatment of diabetes and related disorders. The meeting will be uniquely led by experienced drug-hunters with world-class academic credentials to help foster the translation of basic science to breakthrough therapeutics. We anticipate that this meeting will be of interest to a broad and diverse group of individuals interested in drug discovery and cost-effective development with an emphasis on quality, speed and value.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


The meeting will begin on Sunday, April 17 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Wednesday, April 20 with a closing plenary session from 16:30 to 19:00, followed by a social hour and entertainment. We recommend return travel on Thursday, April 21 in order to fully experience the meeting.

SUNDAY, APRIL 17

16:00—20:00
Arrival and Registration

La Jolla Prefunction
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

La Jolla Prefunction

MONDAY, APRIL 18

07:30—08:30
Breakfast

La Jolla/Pacifica
08:30—09:30
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

La Jolla Ballroom
* Matthias H. Tschöp, Helmholtz Zentrum München and Technische Universität München, Germany

* Nancy A. Thornberry, Kallyope, Inc., USA

Joseph L. Goldstein, University of Texas Southwestern Medical Center, USA
A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins

09:30—11:45
Identification of Breakthrough Therapies for the Treatment of Diabetes and Obesity: Challenges and Opportunities
Meeting has ended...abstracts no longer viewable online.

La Jolla Ballroom
* Eleftheria Maratos-Flier, Beth Israel Deaconess Medical Center, USA

* Jeffrey Flier, Harvard University, USA

Philip Home, Newcastle University, UK
Developing New Therapies for the Management of Type 2 Diabetes

Steven R. Smith, Florida Hospital, USA
Current State of Therapy in Treatment of Obesity

Alan Moses, Novo Nordisk, Denmark
Negotiating Late-Stage Hurdles on the Path from Molecule to Medicine

Marcus Hompesch, Profil Institute, USA
Short Talk: Translational Metabolic Medicine: An Early Phase Clinical Research Perspective

Francois Briand, Physiogenex, France
Short Talk: Journal of Lipid Research Lectureship Junior Investigator Award: Empagliflozin Moderately Increases LDL-Cholesterol Levels through Reduced LDL Catabolism while it Increases Slightly the Reverse Cholesterol Transport in Hamsters

10:00—10:15
Coffee Break

La Jolla Prefunction
11:45—14:30
On Own for Lunch

11:45—13:00
Poster Setup

Pacifica Ballroom
13:00—22:00
Poster Viewing

Pacifica Ballroom
14:30—16:00
Panel: Perspectives on Future Treatment of Metabolic Diseases and Remaining Unmet Needs

La Jolla Ballroom
* Nancy A. Thornberry, Kallyope, Inc., USA

Philip Home, Newcastle University, UK

Robert Henry, University of California San Diego/VA Healthcare System/San Diego, USA

Philip J. Larsen, Sanofi, Germany

Alan Moses, Novo Nordisk, Denmark

16:00—16:30
Coffee Available

La Jolla Prefunction
16:30—19:00
New Therapeutics: Late-Breaking Clinical Data
Meeting has ended...abstracts no longer viewable online.
The organizers propose to query leaders in pharma and biotech to find out what novel and transformative clinical data will be available for presentation at meeting time. We propose a latebreaking session to ensure the most exciting, recent results are presented. Speakers will be selected based on recent developments in drug discovery worldwide and all attempts will be made to include women and minorities. The organizers would like maximal flexibility in this session to ensure a strong program. Potential short and long topics and speakers/institutes include the following:

La Jolla Ballroom
* Bei B. Zhang, Lilly China Research and Development Co., Ltd., China

* Daniel Porte Jr., University of California, San Diego, USA

Philip J. Larsen, Sanofi, Germany
Antihyperglycemic and Weight Loss Effects of a Novel Dual GLP1R/GCGR Agonist, SAR425899, in Obese People with Type 2 Diabetes

David E. Moller, Eli Lilly and Company, USA
Combinatorial Approaches to Achieve Metabolic Control

Lars Fogh Iversen, Novo Nordisk A/S, Denmark
Oral Protein and Peptide Delivery in Diabetes

Keith M. Gottesdiener, Rhythm Pharmaceuticals, USA
Short Talk: Setmelanotide, A New Melanocortin-4 Receptor (MC4R) Peptide Agonist being studied in Patients with Deficiencies in the MC4R Pathway

Peter Kuehnen, Institute for Experimental Pediatric Endocrinology, Germany
Short Talk: Successful Therapy of Extreme Obesity in two POMC Deficient Patients with the Melanocortin-4 Receptor Agonist Setmelanotide

Weiyi Chen, Monash University, Australia
Short Talk: Alpha-Melanocyte Stimulating Hormone Regulates Glucose Homeostasis via Melanocortin-5 Receptor Expressed in Skeletal Muscle

Thomas E. Hughes, Zafgen, Inc, USA
Short Talk: MetAP2 Inhibition as a Therapeutic Approach in Severe and Complicated Obesity

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

La Jolla/Pacifica
19:30—22:00
Poster Session 1

Pacifica Ballroom

TUESDAY, APRIL 19

07:30—08:30
Breakfast

La Jolla/Pacifica
08:30—11:30
Novel Insulins and Insulin Action
Meeting has ended...abstracts no longer viewable online.

La Jolla Ballroom
* Carrie Haskell-Luevano, University of Minnesota, USA

* Simeon Taylor, University of Maryland School of Medicine, USA

Richard D. DiMarchi, Indiana University, USA
New Insulin Analogs for the Treatment of Insulin-Dependent Diabetes

Aaron Kowalski, Juvenile Diabetes Research Foundation International, USA
Utilizing a Diabetes Scorecard to Guide New Therapeutic Research and Development

Timothy Kieffer, University of British Columbia, Canada
Treating Diabetes with Differentiated Pluripotent Stem Cells

Matthias G. von Herrath, La Jolla Institute, USA
Pathogenesis and New Treatment Options for Human Type 1 Diabetes

Michael C. Lawrence, Walter and Eliza Hall Institute of Medical Research, Australia
Short Talk: Structural Analysis of an Insulin Receptor Agonist Interacting with the Receptor's Ectodomain

Carolin Daniel, Helmholtz Zentrum Muenchen, Germany
Short Talk: Novel Type 1 Diabetes Vaccine Candidates Promote Human Foxp3+Treg Induction in Humanized Mice in vivo

Anne Fougerat, CHU Sainte Justine Research Centre, Canada
Short Talk: Neuraminidase 1 Positively Regulates Insulin Signaling

10:00—10:15
Coffee Break

La Jolla Prefunction
11:30—14:30
On Own for Lunch

11:30—13:00
Poster Setup

Pacifica Ballroom
13:00—22:00
Poster Viewing

Pacifica Ballroom
14:30—16:00
Workshop: Sponsored by Janssen Research and Development, LLC.

La Jolla Ballroom
* Annette Schürmann, German Institute of Human Nutrition Potsdam-Rehbruekce, Germany

* Michael A. Cowley, Monash University, Australia

Peter J. Havel, University of California, Davis, USA
The UC Davis Type-2 Diabetes Rat: An Improved Rodent Model for Evaluating New Therapies for the Prevention and Treatment of Type-2 Diabetes Mellitus

Tommaso Poggioli, Harvard Medical School, USA
Exogenous GDF11 Improves Insulin Sensitivity and Glucose Tolerance in Aging Mice on High Fat Diet

Shengkan V. Jin, Rutgers University-Robert Wood Johnson Medical School, USA
Niclosamide Ethanolamine–Induced Mild Mitochondrial Uncoupling Improves Diabetic Symptoms in Mice

Daniel Lindén, AstraZeneca, Sweden
Targeting Foxo1 using cEt Antisense Oligonucleotides Improves Glucose Homeostasis in db/db and Alloxan-Induced Diabetic Mice

S.R. Murthy Madiraju, Montreal Diabetes Research Center, CR-CHUM, Canada
Identification of a Mammalian Glycerol-3-Phosphate Phosphatase: Role in Metabolism and Signaling in Pancreatic Beta–Cells and Hepatocytes

Andreas Stahl, University of California, Berkeley, USA
Engineering Brown Adipose Tissue

16:00—16:30
Coffee Available

La Jolla Prefunction
16:30—19:00
Emerging Areas in Drug Discovery
Meeting has ended...abstracts no longer viewable online.

La Jolla Ballroom
* Ana Domingos, Fundação Calouste Gulbenkian, Portugal

* Edward A. Dennis, University of California, San Diego, USA

Jeffrey M. Friedman, Rockefeller University, USA
CNS Control of Metabolism: New Opportunities

Markus Stoffel, ETH Zürich, Switzerland
Discovery of New RNA-Based Therapeutics for the Treatment of Metabolic Diseases

Umut Ozcan, Boston Children's Hospital, Harvard Medical School, USA
Small Molecule Leptin Sensitizers For Treatment of Obesity

Barbara B. Kahn, Beth Israel Deaconess Medical Center, Harvard Medical School, USA
Journal of Lipid Research Lectureship Introduced by JLR Editor-in-Chief, Edward A. Dennis: The Role of Endogenous Lipids in Metabolic Diseases

Junichiro Sonoda, Genentech, Inc., USA
Short Talk: Endopeptidase FAP Cleaves and Inactivates FGF21

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

La Jolla/Pacifica
19:30—22:00
Poster Session 2

Pacifica Ballroom

WEDNESDAY, APRIL 20

07:30—08:30
Breakfast

La Jolla/Pacifica
08:30—11:30
New Therapeutics in Gut Biology
Meeting has ended...abstracts no longer viewable online.

La Jolla Ballroom
* Birgitte Andersen, Novo Nordisk, Denmark

* Matthias Blüher, University of Leipzig, Germany

Thue W. Schwartz, University of Copenhagen, Denmark
Metabolite versus Hormone Receptors - Playing on the Full Enteroendocrine and Pancreatic Orchestra versus Single Instruments

Daniel J. Drucker, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Canada
New Therapeutic Opportunities in Gut Biology: Balancing Risks and Benefits

Matthias H. Tschöp, Helmholtz Zentrum München and Technische Universität München, Germany
Novel Combination Therapeutics for Diabetes and Obesity

Michael W. Schwartz, University of Washington, USA
Targeting the Brain to Induce Diabetes Remission

Maria Carmen Valcarce Lopez, vTv Therapeutics LLC, USA
Short Talk: Oral Small Molecule GLP-1 Receptor (GLP-1R) Agonists for Type 2 Diabetes (T2DM) with Negligible Nausea and Vomiting

Sofiya Gancheva, German Diabetes Center, Germany
Short Talk: Lack of an Effect of Non-Invasive Vagus Nerve Stimulation on Endogenous Glucose Production and Energy Metabolism in Healthy Humans

Gary Deng, Eli Lilly and Company, USA
Short Talk: Pharmacological Inhibition of PDE4 Mediates Pleiotropic Metabolic Benefits in Diet-Induced Obese Mice and Type 2 Diabetes Patients

10:00—10:15
Coffee Break

La Jolla Prefunction
11:30—14:30
On Own for Lunch

14:30—16:00
Panel: Emerging Models for Non-Conventional Approaches to Drug Discovery with an Emphasis on Partnerships

La Jolla Ballroom
* Alain Baron, Elcelyx Thereapeutics Inc., USA

Jerrold M. Olefsky, University of California, San Diego, USA

Mark D. Erion, Janssen Pharmaceutical, USA

Aaron Kowalski, Juvenile Diabetes Research Foundation International, USA

Steven R. Smith, Florida Hospital, USA

16:00—16:30
Coffee Available

La Jolla Prefunction
16:30—18:45
New Target Discovery
Meeting has ended...abstracts no longer viewable online.

La Jolla Ballroom
* Effie Tzameli, Cell Press, USA

* Martin Hrabé de Angelis, Helmholtz Zentrum München and Technische Universität München, Germany

Kevin L. Grove, Novo Nordisk and Oregon National Primate Research Center, USA
Utility of Non-Human Primates for New Target Validation

Hui Tian, NGM Biopharma, USA
Identification of Novel Mediators of the Beneficial Metabolic Effects of Gastric Bypass

Arun Sharma, MedImmune, USA
Short Talk: Neurturin Prevents Hyperglycemia in Zucker Diabetic Fatty Rats via a Mechanism Distinct from GLP-1 Receptor Agonists

Katrin J. Svensson, Dana-Farber Cancer Institute, USA
Short Talk: A Secreted Slit2 Fragment Regulates Adipose Tissue Thermogenesis and Metabolic Function

Adriano Maida, Helmholtz Zentrum Munich, Germany
Short Talk: Hepatic Transforming Growth Factor Beta-Like Stimulated Clone 22 D4 (TSC22D4) Controls Systemic Insulin Resistance and Type 2 Diabetes

Ronald M. Evans, Howard Hughes Medical Institute, Salk Institute, USA
Nuclear Receptors: Feast, Famine and Physiology

18:45—19:00
Meeting Wrap-Up: Outcomes and Future Directions

La Jolla Ballroom
* Richard D. DiMarchi, Indiana University, USA

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

La Jolla/Pacifica
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Pacifica Ballroom

THURSDAY, APRIL 21

 
Departure


*Session Chair †Invited, not yet responded.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Arena Pharmaceuticals, Inc. Janssen Research and Development, LLC
Merck & Co., Inc. Novo Nordisk A/S
Regeneron Pharmaceuticals, Inc.
 

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge additional support for this conference from:

Journal of Lipid Research Educational grant from Lilly
Mercodia, Inc. Profil® Institute for Clinical Research, Inc.
Translational Research Institute for Metabolism and Diabetes
 

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 5R13DK104616-02

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Novo Nordisk A/S


Novo Nordisk Pharmaceuticals, Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Assistant Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676